Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434868 | 0.84 | FUCA1 (0.49) | ACHEBACE1BCHECXCR4FUCA1 | |
| SCHEMBL11413096 | 0.81 | FUCA1 (0.60) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL4128561 | 0.81 | KDM1A (0.50) | ACHEBACE1BCHEFUCA1KDM1A | |
| SCHEMBL4189224 | 0.81 | GRIN2B (0.48) | FUCA1DRD2DRD3SIGMAR1 | |
| SCHEMBL16837173 | 0.79 | FUCA1 (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL4191012 | 0.79 | FUCA1 (0.50) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL4198217 | 0.79 | FUCA1 (0.54) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL21737903 | 0.78 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL3212351 | 0.78 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL26709643 | 0.78 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | ACHE 218/4885BACE1 2901/4885BCHE 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.